Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

Screenshot 2016 11 18 at 11.23.36 AM e1479464682197

News and Trends 18 Nov 2016

These Spider Silk Sneakers from Adidas Are Biodegradable

Adidas just unveiled a biodegradable sneaker prototype made with a spider silk biomaterial manufactured by the German biotech AMSilk. Is this the beginning of a new era for sustainable biomaterials? AMSilk, located near Munich, is the world’s first biotech supplying synthetic silk biopolymers for textiles, cosmetics and medical devices. The company’s 100% biodegradable and vegan […]

November 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 17 at 5.37.49 PM e1479400708474

News and Trends 18 Nov 2016

Can Oncolytic Viruses be the key to Treat Resistant Tumors?

This week, we leave Belgium and keep traveling north to Oslo, where snow is starting to pack for the joy of skiers. Meanwhile, Targovax is there working hard to treat cancer with its immunotherapy pipeline. City: Oslo, Norway Founded: 2010 Employees: 20 – 30 Financial data: €12M raised in a private placement in July Mission: Targovax develops immuno-oncology […]

November 18, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

Boehringer Ingelheim is getting ready to launch a biosimilar for Roche’s cancer blockbuster Avastin as soon as the patent expires. Can it overcome the fierce competition in a market expected to grow to 50% of the drug market by 2020? Boehringer Ingelheim just announced results from a Phase I trial showing that its biosimilar candidate […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

Germany steps up the fight against the Most Painful Disease

Grünenthal just acquired Thar Pharmaceuticals to pave the way towards treating complex regional pain syndrome (CRPS), considered one of the most painful conditions. Grünenthal, the company behind the thalidomide scandal in the 60s due to childbirth deformities, is now focusing on complex regional pain syndrome (CRPS), a rare orphan disease that causes prolonged and intense pain. In order […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

New Private Placement to Boost the Profitable Therapeutic Antibody Market

MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021. MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology. Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

CRISPR meets RNAi: a whole new Targeted Therapy

Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed

Erytech will have to provide additional data before re-applying for market approval in Europe for Graspa. This leukemia therapy uses red blood cells to deliver an enzyme that starves tumors to death. Erytech is a biotech from Lyon with a visionary approach to treat cancer: using red blood cells as drug carriers. Last year, the company […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 08 at 3.21.24 PM e1478614975174

News and Trends 12 Nov 2016

The sound of this Spider Silk Violin surprises Expert Musicians

Last week, Imperial College London hosted the International Student Innovation Awards. The winner astonished everyone with a violin made with spider silk. Luca Alessandrini was awarded the £10,000 prize for the design of a biomaterial-based violin that can be engineered to customize the final sound. With the new funds and a patent filed, the designer is now looking for co-founders to […]

November 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Nov 2016

European Biotech is working hard to Beat back Melanoma

Immunocore and Pierre Fabre have been representing Europe in this years’ Society for Melanoma Research Congress. This type of cancer may have its days counted! This week, scientists from around the globe met at the MRC to get an update on what’s going on in the fights against melanoma, the least common but most deadly skin […]

November 10, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

These Spider Silk Sneakers from Adidas Are Biodegradable

Can Oncolytic Viruses be the key to Treat Resistant Tumors?

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

Germany steps up the fight against the Most Painful Disease

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

New Private Placement to Boost the Profitable Therapeutic Antibody Market

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

CRISPR meets RNAi: a whole new Targeted Therapy

Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed

The sound of this Spider Silk Violin surprises Expert Musicians

European Biotech is working hard to Beat back Melanoma

Subscribe to our newsletter to get the latest biotech news!